Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endometrial tissue refers to the mucosal lining of the uterus, which undergoes cyclical changes under hormonal regulation. Suppression of endometrial tissue is a therapeutic target in conditions such as endometriosis, where endometrium-like tissue grows outside the uterine cavity and causes pain, inflammation, and infertility. Key molecular targets for suppression include estrogen receptors, progesterone receptor, matrix metalloproteinases, and immune modulation.
Suppression strategies focus on: - Blocking estrogen action via selective estrogen receptor modulators or aromatase inhibitors. - Enhancing progesterone response or mimicking its effects with progestins; however, efficacy may be limited by intrinsic progesterone resistance due to reduced PGR levels or function. - Inhibiting matrix metalloproteinases to prevent invasion/spread of ectopic tissue. - Modulating immune responses to enhance clearance of aberrant tissues.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endometrial Tissue (Suppression).